Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 9, 2013

DARPA Awards Techulon $1.9M to Develop ‘Superbug’ Drug

  • The Defense Advanced Research Projects Agency (DARPA) has awarded Techulon $1.9 million to advances its therapeutic program for multidrug-resistant bacteria, so-called superbugs, through a Phase II contract, the nucleic acid therapeutics development firm said.

    Through this award, Techulon aims to advance the development of a nanotherapeutic agent through critical milestones toward clinical trials, the company added.

    “We are pleased to extend our work in Rapidly Adaptable Therapeutics with DARPA. This program will lead to better therapies for wounded soldiers and civilians affected by multi-drug resistant hospital-acquired infections,” Techulon CSO Joshua Bryson, Ph.D., said in a statement.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »